Dare Bioscience (DARE) Stock Price, News & Analysis

Company Overview

Daré Bioscience, Inc. (NASDAQ: DARE) is a biopharmaceutical company focused on developing and commercializing therapies designed to address unmet needs in women’s health. The company’s research and development activities span contraception, vaginal health, sexual health and reproductive health, with an emphasis on pharmaceutical products and drug-delivery technologies.

Daré’s lead commercial product is XACIATO (clindamycin phosphate) vaginal gel 2%, an FDA-approved prescription treatment for bacterial vaginosis in females 12 and older. Daré developed the product and entered into an agreement with Organon for its commercialization in the United States. The company also has investigational programs, including Ovaprene, a non-hormonal monthly contraceptive, and other potential treatments for conditions affecting women’s sexual and reproductive health. These candidates remain subject to clinical development and regulatory review.

Headquartered in San Diego, California, Daré serves the women’s health market primarily through development partnerships, licensing arrangements and potential commercialization activities in the United States and other markets. The company was founded to advance innovative therapies for women and is led by founder and Chief Executive Officer Sabrina Martucci Johnson.

Key Stats

• Today's Range: $0.62 to $0.65
• 50-Day Range: $0.62 to $0.85
• 52-Week Range: $0.61 to $3.78
• Volume: 52,988 shs
• Average Volume: 147,612 shs
• Market Capitalization: $12.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

Dare Bioscience Stock Analysis - MarketRank™

Dare Bioscience scored higher than 35% of companies evaluated by MarketBeat, and ranked 705th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Dare Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Dare Bioscience has a consensus price target of $5.00, representing about 682.5% upside from its current price of $0.64.

Amount of Analyst Coverage

Dare Bioscience has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Dare Bioscience are expected to grow in the coming year, from ($0.74) to ($0.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dare Bioscience is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dare Bioscience is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dare Bioscience has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.02% of the float of Dare Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Dare Bioscience has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Dare Bioscience has recently increased by 24.04%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dare Bioscience does not currently pay a dividend.

Dividend Growth

Dare Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Dare Bioscience this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for DARE on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Dare Bioscience to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dare Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.40% of the stock of Dare Bioscience is held by insiders.

Percentage Held by Institutions

6.70% of the stock of Dare Bioscience is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/08/2026
• EGM 2026: 11/10/2026
• Stifel 2026 Healthcare Conference 2026: 11/11/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:DARE
• CIK: 1401914
• Web: www.darebioscience.com
• Phone: (858) 926-7655
• Fax: 617-494-1544
• Employees: 24
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Dare Bioscience: $5.00
• High Price Target: $12.00
• Low Price Target: $1.00
• Potential Upside/Downside: +682.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.40 million
• Net Margins: -803.80%
• Pretax Margin: -803.80%
• Return on Equity: -748.30%
• Return on Assets: -38.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.99
• Quick Ratio: 0.99

Sales & Book Value

• Annual Sales: $1.37 million
• Price / Sales: 9.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 3.20

Miscellaneous

• Outstanding Shares: 19,669,000
• Free Float: 19,000,000
• Market Cap: $12.57 million
• Optionable: Not Optionable
• Beta: 1.11